Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
- DOI
- 10.1038/s41591-026-04534-z
- Published
- 2026 Aug
- Container
- Nature medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-026-04534-z,
title = {Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.},
author = {Porter ML and Martorell A and Sayed CJ and Bechara FG and Lev-Tov H and Hsiao JL and Frew JW and Reguiaï Z and Gooderham MJ and Goldfarb N and van der Zee HH and Del Marmol V and Marzano AV and Ehst BD and Ackerman LS and Hayama K and Tian C and Kelley J and Zhen H and Kirby JS and Brown K and Santos LL and Zouboulis CC},
year = {2026},
journal = {Nature medicine},
doi = {10.1038/s41591-026-04534-z},
url = {https://doi.org/10.1038/s41591-026-04534-z}
}RIS
TY - JOUR TI - Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. AU - Porter ML AU - Martorell A AU - Sayed CJ AU - Bechara FG AU - Lev-Tov H AU - Hsiao JL AU - Frew JW AU - Reguiaï Z AU - Gooderham MJ AU - Goldfarb N AU - van der Zee HH AU - Del Marmol V AU - Marzano AV AU - Ehst BD AU - Ackerman LS AU - Hayama K AU - Tian C AU - Kelley J AU - Zhen H AU - Kirby JS AU - Brown K AU - Santos LL AU - Zouboulis CC PY - 2026 JO - Nature medicine DO - 10.1038/s41591-026-04534-z UR - https://doi.org/10.1038/s41591-026-04534-z ER -
APA
ML, P., A, M., CJ, S., FG, B., H, L., JL, H., JW, F., Z, R., MJ, G., N, G., HH, V. D. Z., V, D. M., AV, M., BD, E., LS, A., K, H., C, T., J, K., H, Z., JS, K., K, B., LL, S., & CC, Z. (2026). Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.. Nature medicine. https://doi.org/10.1038/s41591-026-04534-z
Source records
- pubmed · retrieved 2026-09-26T04:58:06.665Z